Acadia Pharmaceuticals Inc [ACAD] stock prices are up 0.68% to $17.77 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The ACAD shares have gain 10.17% over the last week, with a monthly amount glided 18.23%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Acadia Pharmaceuticals Inc [NASDAQ: ACAD] stock has seen the most recent analyst activity on June 27, 2024, when BMO Capital Markets initiated its Outperform rating and assigned the stock a price target of $31. Previously, Needham reaffirmed its Buy rating on March 12, 2024, and dropped its price target to $32. On March 12, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $25 on the stock. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $40 on January 30, 2024. Needham upgraded its rating to a Buy but $37 remained the price target by the analyst firm on January 24, 2024. Morgan Stanley upgraded its rating to Overweight for this stock on December 19, 2023, and upped its price target to $40. In a note dated December 14, 2023, Deutsche Bank downgraded an Hold rating on this stock but restated the target price of $25.
The stock price of Acadia Pharmaceuticals Inc [ACAD] has been fluctuating between $14.55 and $33.99 over the past year. Currently, Wall Street analysts expect the stock to reach $26.48 within the next 12 months. Acadia Pharmaceuticals Inc [NASDAQ: ACAD] shares were valued at $17.77 at the most recent close of the market. An investor can expect a potential return of 49.02% based on the average ACAD price forecast.
Analyzing the ACAD fundamentals
The Acadia Pharmaceuticals Inc [NASDAQ:ACAD] reported sales of 813.81M for trailing twelve months, representing a surge of 73.75%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -0.01%, Pretax Profit Margin comes in at 0.02%, and Net Profit Margin reading is -0.0%. To continue investigating profitability, this company’s Return on Assets is posted at -0.0, Equity is -0.0 and Total Capital is -0.01. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.51 points at the first support level, and at 17.26 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.05, and for the 2nd resistance point, it is at 18.34.
Ratios To Look Out For
It’s worth pointing out that Acadia Pharmaceuticals Inc [NASDAQ:ACAD]’s Current Ratio is 2.04. On the other hand, the Quick Ratio is 1.86, and the Cash Ratio is 0.62. Considering the valuation of this stock, the price to sales ratio is 3.61, the price to book ratio is 6.32.
Transactions by insiders
Recent insider trading involved Schneyer Mark C., EVP, CHIEF FINANCIAL OFFICER, that happened on Jun 10 ’24 when 975.0 shares were sold. CEO, DAVIS STEPHEN completed a deal on May 02 ’24 to sell 11427.0 shares. Meanwhile, EVP, CHIEF FINANCIAL OFFICER Schneyer Mark C. sold 3503.0 shares on May 02 ’24.
